Chemotherapy with nivolumab in advanced gastro-oesophageal adenocarcinoma

被引：4
|
作者：
Fong, Caroline [1 ,2 ]
Cunningham, David [1 ,2 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Gastrointestinal & Lymphoma Unit, London SW3 6JJ, England
[2] Royal Marsden NHS Fdn Trust, Gastrointestinal & Lymphoma Unit, Sutton, Surrey, England
来源：
LANCET | 2021年 / 398卷 / 10294期
关键词：
ESOPHAGEAL; CANCER;
D O I：
10.1016/S0140-6736(21)00988-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2 / 3
页数：2
相关论文
共 50 条
  • [31] Operable gastro-oesophageal junctional adenocarcinoma: Where to next?
    Elizabeth C Smyth
    David Cunningham
    World Journal of Gastrointestinal Oncology, 2014, (06) : 145 - 155
  • [32] Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia
    McColl, Kenneth E. L.
    Going, James J.
    GUT, 2010, 59 (03) : 282 - 284
  • [33] Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma
    Badgwell, Brian
    Blum, Mariela
    Estrella, Jeannelyn
    Ajani, Jaffer
    LANCET ONCOLOGY, 2016, 17 (12): : 1628 - 1629
  • [34] Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review
    Carter, Gebra Cuyun
    King, Denise T.
    Hess, Lisa M.
    Mitchell, Stephen A.
    Taipale, Kaisa-Leena
    Kiiskinen, Urpo
    Rajan, Narayan
    Novick, Diego
    Liepa, Astra M.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (11) : 954 - 966
  • [35] A SYSTEMATIC REVIEW OF HEALTH-STATE UTILITY VALUES IN ADVANCED GASTRIC, OESOPHAGEAL, OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA
    Carter, Cuyun G.
    King, D. T.
    Mitchell, S. A.
    Hess, L. M.
    Taipale, K. L.
    Kiiskinen, U.
    Rajan, N.
    Novick, D.
    Liepa, A. M.
    VALUE IN HEALTH, 2014, 17 (03) : A92 - A92
  • [36] Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma
    Windsor, ACJ
    Somers, SS
    Crellin, A
    Hassan, S
    Macadam, R
    Sadek, SA
    Guillou, PJ
    Reynolds, JV
    SURGICAL ONCOLOGY-OXFORD, 1995, 4 (05): : 277 - 279
  • [37] ECONOMIC EVALUATION OF RAMUCIRUMAB AS SECOND-LINE CHEMOTHERAPY FOR PREVIOUSLY TREATED ADVANCED GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA IN CHINA
    Luo, X.
    Peng, L.
    Tan, C.
    Wan, X.
    Zeng, X.
    VALUE IN HEALTH, 2018, 21 : S33 - S33
  • [38] Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux
    Rubenstein, J. H.
    Taylor, J. B.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (10) : 1222 - 1227
  • [39] GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) SYMPTOMATOLOGY IS NOT A RELIABLE PREDICTOR OF OESOPHAGEAL ADENOCARCINOMA
    Sugumaran, A.
    Rasheed, A.
    GUT, 2013, 62 : A194 - A194
  • [40] GASTRO-OESOPHAGEAL REGURGITATION
    LAWLER, NA
    MCCREATH, ND
    LANCET, 1951, 261 (SEP1): : 369 - 374
12345